OA11286A - 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4receptor. - Google Patents

2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4receptor. Download PDF

Info

Publication number: OA11286A
Authority: OA; OAPI
Prior art keywords: disorders; fluoro; piperazin; dopamine; compound according
Prior art date: 1997-08-15

Application number

OA1200000030A

Other languages

English (en)

Inventor

Anton Franz Josef Fliri

Mark Jerome Majchrzak

Hans Rollema

Patricia Ann Seymour

Stevin Howard Zorn

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-15

Filing date

2000-02-08

Publication date

2003-10-22

2000-02-08 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-10-22 Publication of OA11286A publication Critical patent/OA11286A/en

Links

108090000357 Dopamine D4 receptors Proteins 0.000 title description 2
102000003962 Dopamine D4 receptors Human genes 0.000 title description 2
229940054051 antipsychotic indole derivative Drugs 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 54
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 31
229960003638 dopamine Drugs 0.000 claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
208000035475 disorder Diseases 0.000 claims description 31
229910052739 hydrogen Inorganic materials 0.000 claims description 19
239000001257 hydrogen Substances 0.000 claims description 19
241000124008 Mammalia Species 0.000 claims description 16
125000001309 chloro group Chemical group Cl* 0.000 claims description 15
125000001153 fluoro group Chemical group F* 0.000 claims description 14
201000009032 substance abuse Diseases 0.000 claims description 14
208000028017 Psychotic disease Diseases 0.000 claims description 13
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 13
239000000126 substance Substances 0.000 claims description 13
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
229910052757 nitrogen Inorganic materials 0.000 claims description 10
101150043870 Drd4 gene Proteins 0.000 claims description 9
208000018522 Gastrointestinal disease Diseases 0.000 claims description 9
208000016285 Movement disease Diseases 0.000 claims description 9
208000011117 substance-related disease Diseases 0.000 claims description 9
208000019116 sleep disease Diseases 0.000 claims description 8
231100000736 substance abuse Toxicity 0.000 claims description 8
208000018737 Parkinson disease Diseases 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 7
125000001246 bromo group Chemical group Br* 0.000 claims description 7
239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 7
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
230000002792 vascular Effects 0.000 claims description 7
208000024172 Cardiovascular disease Diseases 0.000 claims description 6
206010047700 Vomiting Diseases 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
230000000694 effects Effects 0.000 claims description 6
208000019553 vascular disease Diseases 0.000 claims description 6
208000017194 Affective disease Diseases 0.000 claims description 5
206010007559 Cardiac failure congestive Diseases 0.000 claims description 5
206010019280 Heart failures Diseases 0.000 claims description 5
201000005625 Neuroleptic malignant syndrome Diseases 0.000 claims description 5
201000000980 schizophrenia Diseases 0.000 claims description 5
206010020772 Hypertension Diseases 0.000 claims description 4
206010043118 Tardive Dyskinesia Diseases 0.000 claims description 4
150000002431 hydrogen Chemical group 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
208000022873 Ocular disease Diseases 0.000 claims description 3
208000000323 Tourette Syndrome Diseases 0.000 claims description 3
239000003176 neuroleptic agent Substances 0.000 claims description 3
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 7
201000010099 disease Diseases 0.000 claims 1
230000002526 effect on cardiovascular system Effects 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 5
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 89
238000004458 analytical method Methods 0.000 description 62
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 47
235000011087 fumaric acid Nutrition 0.000 description 41
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 20
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
-1 (CrCejalkoxy Chemical group 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
125000000217 alkyl group Chemical group 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
238000005481 NMR spectroscopy Methods 0.000 description 7
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000000556 agonist Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
125000004093 cyano group Chemical group *C#N 0.000 description 5
238000000034 method Methods 0.000 description 5
239000007787 solid Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
208000023105 Huntington disease Diseases 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
210000004211 gastric acid Anatomy 0.000 description 4
229940073584 methylene chloride Drugs 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
239000003880 polar aprotic solvent Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000006071 cream Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000002674 ointment Substances 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 3
229950001037 quinpirole Drugs 0.000 description 3
DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
SVDHOCZCQXVPOU-UHFFFAOYSA-N 5-fluoro-1h-indole-2-carbaldehyde Chemical compound FC1=CC=C2NC(C=O)=CC2=C1 SVDHOCZCQXVPOU-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
108050004812 Dopamine receptor Proteins 0.000 description 2
102000015554 Dopamine receptor Human genes 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000865206 Homo sapiens D(4) dopamine receptor Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
125000002015 acyclic group Chemical group 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
229910052681 coesite Inorganic materials 0.000 description 2
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
229910052906 cristobalite Inorganic materials 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
239000006072 paste Substances 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
229960003010 sodium sulfate Drugs 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
229910052682 stishovite Inorganic materials 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
230000005062 synaptic transmission Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229910052905 tridymite Inorganic materials 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
ZZJYIKPMDIWRSN-TZBSWOFLSA-N (+)-butaclamol Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)(C)C)(O)C[C@@H]13 ZZJYIKPMDIWRSN-TZBSWOFLSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
PZTWBYCZTVLVPV-UHFFFAOYSA-N 2-[2-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCCC1CNCCN1CCS(O)(=O)=O PZTWBYCZTVLVPV-UHFFFAOYSA-N 0.000 description 1
HAEDOALGQUCLFO-UHFFFAOYSA-N 2-[[4-(6-chloropyridazin-3-yl)piperazin-1-yl]methyl]-5-fluoro-1h-indole Chemical compound C=1C2=CC(F)=CC=C2NC=1CN(CC1)CCN1C1=CC=C(Cl)N=N1 HAEDOALGQUCLFO-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
WTXBRZCVLDTWLP-UHFFFAOYSA-N 5-fluoro-1H-indole-2-carboxylic acid Chemical compound FC1=CC=C2NC(C(=O)O)=CC2=C1 WTXBRZCVLDTWLP-UHFFFAOYSA-N 0.000 description 1
UMLGAJBWICWJOR-UHFFFAOYSA-N 5-fluoro-1h-indole-2-carbonyl chloride Chemical compound FC1=CC=C2NC(C(Cl)=O)=CC2=C1 UMLGAJBWICWJOR-UHFFFAOYSA-N 0.000 description 1
PQOIDBZLMJMYCD-UHFFFAOYSA-N 5-fluoro-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1h-indole Chemical compound C=1C2=CC(F)=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 PQOIDBZLMJMYCD-UHFFFAOYSA-N 0.000 description 1
MWPFXEHMGAJJCD-UHFFFAOYSA-N 5-fluoro-2-[[4-(4-fluorophenyl)piperazin-1-yl]methyl]-1h-indole Chemical compound C1=CC(F)=CC=C1N1CCN(CC=2NC3=CC=C(F)C=C3C=2)CC1 MWPFXEHMGAJJCD-UHFFFAOYSA-N 0.000 description 1
YXEZZMBABNHVFB-UHFFFAOYSA-N 5-fluoro-2-[[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]-1h-indole Chemical compound C=1C2=CC(F)=CC=C2NC=1CN(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 YXEZZMBABNHVFB-UHFFFAOYSA-N 0.000 description 1
RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
ZSKFERSPBICNGI-UHFFFAOYSA-N 6-fluoro-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC(F)=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 ZSKFERSPBICNGI-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
101100495911 Arabidopsis thaliana CHR10 gene Proteins 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000012267 brine Substances 0.000 description 1
230000001593 cAMP accumulation Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000019771 cognition Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
229940126513 cyclase activator Drugs 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
229940005501 dopaminergic agent Drugs 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003814 drug Substances 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
OWYJZQFASFWUHP-UHFFFAOYSA-N hydroxylamine;1h-indole Chemical compound ON.C1=CC=C2NC=CC2=C1 OWYJZQFASFWUHP-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
YBXBWBBVLXZQBJ-UHFFFAOYSA-N n-[2-(5-hydroxy-2-methyl-1h-indol-3-yl)ethyl]-2-methoxyacetamide Chemical compound C1=C(O)C=C2C(CCNC(=O)COC)=C(C)NC2=C1 YBXBWBBVLXZQBJ-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000009329 sexual behaviour Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
229950001675 spiperone Drugs 0.000 description 1
108010092215 spiroperidol receptor Proteins 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

OA1200000030A 1997-08-15 2000-02-08 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4receptor. OA11286A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US5576497P	1997-08-15	1997-08-15

Publications (1)

Publication Number	Publication Date
OA11286A true OA11286A (en)	2003-10-22

Family

ID=22000003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000030A OA11286A (en)	1997-08-15	2000-02-08	2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4receptor.

Country Status (30)

Country	Link
EP (1)	EP1003739A2 (fr)
JP (1)	JP2002536291A (fr)
KR (1)	KR20010022507A (fr)
CN (1)	CN1265660A (fr)
AP (1)	AP9801321A0 (fr)
AR (1)	AR017019A1 (fr)
AU (1)	AU8457298A (fr)
BG (1)	BG104069A (fr)
BR (1)	BR9811557A (fr)
CA (1)	CA2297486C (fr)
CO (1)	CO4960656A1 (fr)
DZ (1)	DZ2583A1 (fr)
EA (1)	EA200000023A1 (fr)
HR (1)	HRP980441A2 (fr)
HU (1)	HUP0003425A3 (fr)
ID (1)	ID23803A (fr)
IL (1)	IL133960A0 (fr)
IS (1)	IS5336A (fr)
MA (1)	MA24632A1 (fr)
NO (1)	NO20000722L (fr)
OA (1)	OA11286A (fr)
PA (1)	PA8457001A1 (fr)
PE (1)	PE106299A1 (fr)
PL (1)	PL338947A1 (fr)
SK (1)	SK1352000A3 (fr)
TN (1)	TNSN98151A1 (fr)
TR (1)	TR200000414T2 (fr)
UY (1)	UY25144A1 (fr)
WO (1)	WO1999009025A2 (fr)
ZA (1)	ZA987304B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EE04588B1 (et) *	1997-10-27	2006-02-15	Neurosearch A/S	Heteroarüüldiasatsükloalkaanid kui atsetüülkoliini nikotiinretseptorite kolinergilised ligandid, nende kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EP0953567A3 (fr)	1998-04-29	2003-04-02	Pfizer Products Inc.	Dérivés de piperazin-, piperidine- et tetrahydropyridine bicyclique substitués, leur préparation et leur utilisation comme agents a activité dopaminergique (recepteur D4 de la dopamine) centrale
EP1464641B1 (fr) *	1999-12-30	2008-05-14	H. Lundbeck A/S	Dérivés de 4-phenylpiperazinyle, -piperidinyle et -tetrahydropyridyle à titre de antagonistes de dopamine D4
GB0017952D0 (en) *	2000-07-22	2000-09-13	Univ Manchester	Treatment of dyskinesia
EP1177792A3 (fr)	2000-07-27	2002-10-23	Pfizer Products Inc.	Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute
EP1373204B1 (fr)	2001-03-09	2016-10-26	Janssen Pharmaceuticals, Inc.	Composes heterocycliques
WO2004022060A2 (fr)	2002-09-06	2004-03-18	Janssen Pharmaceutica, N.V.	Composes heterocycliques
WO2004108671A1 (fr) *	2003-06-06	2004-12-16	Suven Life Sciences Limited	Indoles substitues dotes d'une affinite pour le recepteur de la serotonine, leur procede de fabrication et compositions pharmaceutiques les contenant
US7517910B2 (en)	2004-03-30	2009-04-14	Takeda Pharmaceutical Company Limited	Alkoxyphenylpropanoic acid derivatives
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
US7618980B2 (en)	2004-07-14	2009-11-17	Bristol-Myers Squibb Company	Pyrrolo(oxo)quinolines as 5HT ligands
JO2769B1 (en) *	2005-10-26	2014-03-15	جانسين فارماسوتيكا ان. في	Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2642B1 (en)	2006-12-08	2012-06-17	جانسين فارماسوتيكا ان. في	Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) *	2007-02-13	2015-03-15	جانسين فارماسوتيكا ان. في	Dopamine 2 receptor antagonists are rapidly hydrolyzed
MX2009011416A (es)	2007-04-23	2009-11-05	Janssen Pharmaceutica Nv	Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
RS52518B (sr)	2007-04-23	2013-04-30	Janssen Pharmaceutica N.V.	Derivati 4-alkoksipiridazina kao brzo disocirajući dopamin 2 receptorski antagonisti
CA2729313C (fr)	2008-07-03	2016-08-30	Janssen Pharmaceutica Nv	6-(1-piperazinyl)-pyridazines substituees comme antagonistes du recepteur 5-ht<sb>6</sb>
ES2622161T3 (es)	2008-07-31	2017-07-05	Janssen Pharmaceutica, N.V.	Piridinas sustituidas con piperazin-1-il-trifluorometilo como antagonistas del receptor de la dopamina 2 de disociación rápida
US11266640B2 (en) *	2017-09-20	2022-03-08	Hangzhou Innogate Pharma Co., Ltd.	Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor
IL296423A (en) *	2020-04-22	2022-11-01	Anima Biotech Inc	Collagen 1 translation inhibitors and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB944443A (fr) *	1959-09-25	1900-01-01
EP0594702B1 (fr) *	1991-07-03	1997-01-29	PHARMACIA & UPJOHN COMPANY	Indoles substitues utilises comme produits pharmaceutiques dans le traitement du sida
JPH05255089A (ja) *	1991-12-18	1993-10-05	Sanwa Kagaku Kenkyusho Co Ltd	抗ウイルス剤
EP0665840A1 (fr) *	1992-10-23	1995-08-09	MERCK SHARP & DOHME LTD.	Ligands pour les sous-types de recepteurs de dopamine
US5576336A (en) *	1993-03-18	1996-11-19	Merck Sharp & Dohme Limited	Indole derivatives as dopamine D4 antagonists
GB9305644D0 (en) *	1993-03-18	1993-05-05	Merck Sharp & Dohme	Therapeutic agents
AU6435594A (en) *	1993-04-15	1994-11-08	Merck Sharp & Dohme Limited	Indole derivatives as dopamine d4 antagonists
DE4414113A1 (de) *	1994-04-22	1995-10-26	Merck Patent Gmbh	3-Indolylpiperidine
TW406075B (en) *	1994-12-13	2000-09-21	Upjohn Co	Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
ZA968661B (en) *	1995-11-17	1998-04-14	Upjohn Co	Oxazolidinone antibacterial agent with tricyclic substituents.
TW504510B (en) *	1996-05-10	2002-10-01	Janssen Pharmaceutica Nv	2,4-diaminopyrimidine derivatives

1998
- 1998-08-05 IL IL13396098A patent/IL133960A0/xx unknown
- 1998-08-05 CN CN98807831A patent/CN1265660A/zh active Pending
- 1998-08-05 SK SK135-2000A patent/SK1352000A3/sk unknown
- 1998-08-05 AP APAP/P/1998/001321A patent/AP9801321A0/en unknown
- 1998-08-05 TR TR2000/00414T patent/TR200000414T2/xx unknown
- 1998-08-05 CA CA002297486A patent/CA2297486C/fr not_active Expired - Fee Related
- 1998-08-05 AU AU84572/98A patent/AU8457298A/en not_active Abandoned
- 1998-08-05 ID IDW20000197A patent/ID23803A/id unknown
- 1998-08-05 JP JP2000509706A patent/JP2002536291A/ja active Pending
- 1998-08-05 BR BR9811557-0A patent/BR9811557A/pt not_active IP Right Cessation
- 1998-08-05 WO PCT/IB1998/001198 patent/WO1999009025A2/fr not_active Ceased
- 1998-08-05 KR KR1020007001093A patent/KR20010022507A/ko not_active Ceased
- 1998-08-05 PL PL98338947A patent/PL338947A1/xx unknown
- 1998-08-05 EP EP98935229A patent/EP1003739A2/fr not_active Withdrawn
- 1998-08-05 HU HU0003425A patent/HUP0003425A3/hu unknown
- 1998-08-05 EA EA200000023A patent/EA200000023A1/ru unknown
- 1998-08-10 PA PA19988457001A patent/PA8457001A1/es unknown
- 1998-08-10 PE PE1998000717A patent/PE106299A1/es not_active Application Discontinuation
- 1998-08-12 MA MA25210A patent/MA24632A1/fr unknown
- 1998-08-12 DZ DZ980193A patent/DZ2583A1/fr active
- 1998-08-12 TN TNTNSN98151A patent/TNSN98151A1/fr unknown
- 1998-08-13 AR ARP980104021A patent/AR017019A1/es unknown
- 1998-08-14 HR HR60/055,764A patent/HRP980441A2/hr not_active Application Discontinuation
- 1998-08-14 ZA ZA9807304A patent/ZA987304B/xx unknown
- 1998-08-14 CO CO98046788A patent/CO4960656A1/es unknown
- 1998-08-17 UY UY25144A patent/UY25144A1/es not_active Application Discontinuation
2000
- 2000-01-10 BG BG104069A patent/BG104069A/xx unknown
- 2000-01-11 IS IS5336A patent/IS5336A/is unknown
- 2000-02-08 OA OA1200000030A patent/OA11286A/en unknown
- 2000-02-14 NO NO20000722A patent/NO20000722L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20010022507A (ko)	2001-03-15
ZA987304B (en)	2000-02-14
DZ2583A1 (fr)	2003-02-22
NO20000722D0 (no)	2000-02-14
TNSN98151A1 (fr)	2005-03-15
PL338947A1 (en)	2000-12-04
IL133960A0 (en)	2001-04-30
EA200000023A1 (ru)	2000-08-28
AR017019A1 (es)	2001-08-22
PE106299A1 (es)	1999-11-02
UY25144A1 (es)	2000-12-29
ID23803A (id)	2000-05-11
BG104069A (en)	2001-05-31
JP2002536291A (ja)	2002-10-29
TR200000414T2 (tr)	2000-08-21
HRP980441A2 (en)	1999-04-30
EP1003739A2 (fr)	2000-05-31
NO20000722L (no)	2000-02-14
IS5336A (is)	2000-01-11
HUP0003425A3 (en)	2002-02-28
AP9801321A0 (en)	2000-02-14
WO1999009025A2 (fr)	1999-02-25
PA8457001A1 (es)	2000-09-29
CN1265660A (zh)	2000-09-06
SK1352000A3 (en)	2000-08-14
HUP0003425A2 (hu)	2001-10-28
CA2297486A1 (fr)	1999-02-25
AU8457298A (en)	1999-03-08
MA24632A1 (fr)	1999-04-01
CA2297486C (fr)	2005-05-03
CO4960656A1 (es)	2000-09-25
BR9811557A (pt)	2000-08-22
WO1999009025A3 (fr)	1999-04-15

Publication	Publication Date	Title
OA11286A (en)	2003-10-22	2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4receptor.
US8044069B2 (en)	2011-10-25	Compounds as calcium channel blockers
EP2167083B1 (fr)	2015-10-28	1- hétéroaryl-3-azabicyclo[3.1.0]hexanes, leurs méthodes de préparation et leur utilisation comme médicaments
HU227684B1 (en)	2011-11-28	Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
US7049335B2 (en)	2006-05-23	3-azabicyclo[3.1.0]hexane derivatives
EP1909797A2 (fr)	2008-04-16	Dipipérazinyl cétones et analogues apparentés
AU2007307105A1 (en)	2008-04-17	N-substituted-azacyclylamines as histamine-3 antagonists
Andersen et al.	1992	Selective, centrally acting serotonin 5-HT2 antagonists. 2. Substituted 3-(4-fluorophenyl)-1H-indoles
US20080293771A1 (en)	2008-11-27	Azacyclylbenzamide derivatives as histamine-3 antagonists
EP1581522B1 (fr)	2008-02-20	Derives de flavaxate comme antagonistes de recepteurs muscariniques
HU220070B (hu)	2001-10-28	N-szubsztituált aza-biciklo[3.2.0]heptán-származékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
CN101910126B (zh)	2014-04-30	作为大麻素受体之配体的脯氨酸类似物
HUP0303316A2 (hu)	2004-01-28	Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények
AU2002300094B2 (en)	2007-06-14	New octahydro-2H-pyrido[1,2-alpha]pyrazine compounds, a process for their preparation and pharmaceutical compositions containing them
US20040198734A1 (en)	2004-10-07	2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine
Richter et al.	2010	Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3, 4-dihydro-2H-pyrazino [1, 2-a] indol-1-one scaffold
SK42299A3 (en)	1999-12-10	N-(benzothiazol-2-yl) piperidine-1-ethanamine derivatives, their preparation and application in therapeutics
US9133159B2 (en)	2015-09-15	1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
KR101471987B1 (ko)	2014-12-12	일정한 ｃｎｓ-관련 질환을 치료하기 위한 2-알킬-인다졸 화합물
MXPA00001611A (en)	2001-03-05	2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
CZ2000307A3 (cs)	2000-08-16	Deriváty 2-(4-aryI nebo heteroarylpiperazin-1- ylmetyl)-lH-indolu
Kang et al.	2003	Preparation of Diastereomeric β-Aryloxymethylaminoalcohols Containing Nicotinic Acid Moiety and Their Binding Affinity to β 3-Adrenoreceptors
HK1123550A (en)	2009-06-19	Novel 2,3-dihydroindole compounds
MXPA01008842A (es)	2002-05-09	Derivados n-substituidos de imida con actividad serotonergica